BTG plc (BGC-LN)

SeekingAlpha  May 16  Comment  Dec 5  Comment 
VIENNA (dpa-AFX) - BTG plc (BTG.L) announced the inclusion of treatment with PneumRx Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease...  Nov 15  Comment 
LONDON (dpa-AFX) - Healthcare company BTG plc (BTG.L) posted lower profits for the half year, but revenues were up at actual exchange rates, benefited by significant foreign exchange tailwinds from weaker sterling. For the first half, profit...  Jul 14  Comment 
LONDON (dpa-AFX) - BTG plc (BTG.L) reported that its overall performance and trading since 1 April 2016 are in line with expectations, and the Group's underlying guidance for the year, which includes nine months of revenues and costs relating...
Reuters  May 6  Comment 
* Galil Medical announces agreement to acquisition by Btg Plc Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)  Dec 14  Comment 
LONDON (dpa-AFX) - BTG plc (BTG.L) announced the successful outcome of the RENEW study, the pivotal US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx endobronchial coil implant with a medical therapy control...  Jul 15  Comment 
LONDON (dpa-AFX) - Specialist healthcare company BTG plc (BTG.L) announced ahead of its Annual General Meeting that its business has made a good start to the current financial year with overall trading in line with expectations. This is on the...  May 23  Comment 
LONDON (dpa-AFX) - EKOS Corporation, a BTG International group company (BTG plc (BTG.L)), announced that the U.S. Food and Drug Administration has cleared the EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective...
Reuters  May 23  Comment 
BTG PLC : * Acquisition of ekos * Has entered into an agreement to buy ekos corporation for an initial cash of


BTG plc is engaged in development and commercialisation of life science technologies. The company licenses, develops and commercializes pharmaceuticals and has a pipeline of development programmes targeting neurological and other disorders, including varicose veins. The Company also has a substantial and growing revenue stream of milestone payments and royalties from out-licensed products.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki